Drug Profile
Research programme: lysosomal storage diseases therapeutics - Mallinckrodt Pharmaceuticals/NCATS
Alternative Names: Cyclodextrin - Vtesse/NCATS; Delta-tocopherol - Vtesse/NCATS; Niemann-Pick disease therapeutics - Vtesse/NCATS; Tocopherol derivatives - Vtesse/NCATSLatest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator National Institutes of Health (USA)
- Developer National Center for Advancing Translational Sciences; National Institutes of Health (USA)
- Class Cyclodextrins; Tocopherols
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Lysosomal storage diseases
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for research development in Lysosomal storage diseases in USA
- 03 Apr 2017 Vtesse has been acquired by Sucampo Pharmaceuticals
- 20 Jan 2015 Early research in Lysosomal storage diseases in USA (unspecified route)